Persistent activation of the AR signaling program occurs both not only through molecular adaptations of the AR itself but also through a number of accessory oncogenic pathways promoting persistent AR activation, ultimately leading to progressive prostate cancer. This evidence concerns the gene AR and prostate cancer.